Telephone
61.3.9002.5000
Address
Unit A8 2A Westall Road Clayton, Victoria (VIC) 3168
Description
Avecho Biotechnology Ltd. engages in the development and commercialization of human and animal products through its proprietary drug delivery system. It operates under the Production and Human Health segments. The Production segment focuses on manufacturing and sale of TPM and Vital ET for the use in drug delivery and cosmetic formulations. The Human Health segment consists of delivery of pharmaceutical products through gels, injectables and patches including conduct of research and development activities. The company was founded by Mark Gregory Kerr on June 19, 1992 and is headquartered in Clayton, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.0 - 0.02
Trade Value (12mth)
AU$3,020.00
1 week
-12.5%
1 month
-12.5%
YTD
-73.08%
1 year
-61.11%
All time high
0.424765
EPS 3 yr Growth
-360.000%
EBITDA Margin
N/A
Operating Cashflow
-$2m
Free Cash Flow Return
-46.60%
ROIC
-65.50%
Interest Coverage
N/A
Quick Ratio
3.30
Shares on Issue (Fully Dilluted)
1931m
HALO Sector
Healthcare
Next Company Report Date
28-Feb-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
31 October 23 |
September 2023 Quarterly Activities Report & Appendix 4C
×
September 2023 Quarterly Activities Report & Appendix 4C |
31 May 21 |
Chair's Address and CEO Presentation
×
Chair's Address and CEO Presentation |
31 May 21 |
2021 Annual General Meeting Results
×
2021 Annual General Meeting Results |
31 May 21 |
Avecho Biotechnology Limited - Chair's Address and CEO Presentation (AVE-AU)
×
Avecho Biotechnology Limited - Chair's Address and CEO Presentation (AVE-AU) |
31 May 21 |
Avecho Biotechnology Limited - 2021 Annual General Meeting Results (AVE-AU)
×
Avecho Biotechnology Limited - 2021 Annual General Meeting Results (AVE-AU) |
31 January 23 |
December 2022 Quarterly Activities Report & Appendix 4C
×
December 2022 Quarterly Activities Report & Appendix 4C |
31 January 23 |
Avecho Biotechnology Limited - December 2022 Quarterly Activities Report & Appendix 4C (AVE-AU)
×
Avecho Biotechnology Limited - December 2022 Quarterly Activities Report & Appendix 4C (AVE-AU) |
31 January 22 |
December 2021 Quarterly Activities Report & Appendix 4C
×
December 2021 Quarterly Activities Report & Appendix 4C |
31 January 22 |
Avecho Biotechnology Limited - December 2021 Quarterly Activities Report & Appendix 4C (AVE-AU)
×
Avecho Biotechnology Limited - December 2021 Quarterly Activities Report & Appendix 4C (AVE-AU) |
31 August 23 |
Appendix 4D and Half-year Financial Report
×
Appendix 4D and Half-year Financial Report |
30 May 22 |
Chair's Address and CEO Presentation
×
Chair's Address and CEO Presentation |
30 May 22 |
2022 Annual General Meeting Results
×
2022 Annual General Meeting Results |
30 May 22 |
Adoption of New Constitution
×
Adoption of New Constitution |
30 April 21 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
30 April 21 |
Avecho Biotechnology Limited - Notice of Annual General Meeting/Proxy Form (AVE-AU)
×
Avecho Biotechnology Limited - Notice of Annual General Meeting/Proxy Form (AVE-AU) |
29 May 23 |
USPTO allows new TPM manufacturing patent
×
USPTO allows new TPM manufacturing patent |
29 March 22 |
Positive results from AVE's topical CBD pain study
×
Positive results from AVE's topical CBD pain study |
29 July 22 |
June 2022 Quarterly Activities Report & Appendix 4C
×
June 2022 Quarterly Activities Report & Appendix 4C |
29 July 22 |
Avecho Biotechnology Limited - June 2022 Quarterly Activities Report & Appendix 4C (AVE-AU)
×
Avecho Biotechnology Limited - June 2022 Quarterly Activities Report & Appendix 4C (AVE-AU) |
29 August 22 |
Appendix 4D and Half-year Financial Report
×
Appendix 4D and Half-year Financial Report |
29 April 22 |
March 2022 Quarterly Activities Report & Appendix 4C
×
March 2022 Quarterly Activities Report & Appendix 4C |
29 April 22 |
Avecho Biotechnology Limited - March 2022 Quarterly Activities Report & Appendix 4C (AVE-AU)
×
Avecho Biotechnology Limited - March 2022 Quarterly Activities Report & Appendix 4C (AVE-AU) |
28 October 22 |
September 2022 Quarterly Activities Report & Appendix 4C
×
September 2022 Quarterly Activities Report & Appendix 4C |
28 October 22 |
Avecho Biotechnology Limited - September 2022 Quarterly Activities Report & Appendix 4C (AVE-AU)
×
Avecho Biotechnology Limited - September 2022 Quarterly Activities Report & Appendix 4C (AVE-AU) |
28 November 23 |
Expiry of Quoted Options
×
Expiry of Quoted Options |
28 June 23 |
Application for quotation of securities - AVE
×
Application for quotation of securities - AVE |
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.